Eisai Gives Rights for Cancer Drug to Dr. Reddy’s Outside Japan, Asia

Eisai said on March 31 that it has agreed to transfer the exclusive worldwide rights outside Japan and Asia to develop and market its investigational anticancer agent E7777 to India’s Dr. Reddy’s Laboratories. The move comes as the Japanese company...read more